Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...

Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...

Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...

Intellia, from the United States. "For many decades, patients with HAE were faced with a very limited number of treatment ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...